Abbott India Ltd.

Abbott India Ltd. shares declined to a fresh 52-week low of Rs.25,350 on 24 March 2026, reflecting a continuation of the stock’s downward trend amid broader market pressures and company-specific valuation concerns.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This article delves into the implications of these changes, analysing key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios in comparison to historical trends and peer benchmarks, while also considering the company’s recent market performance and sector context.

A sharp decline in Abbott India Ltd. shares has pushed the stock to a fresh 52-week low of Rs 25,437.45 on 23 Mar 2026, marking a significant underperformance relative to both its sector and the broader market indices.

Abbott India Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 09 March 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 9 March 2026. This shift reflects a combination of deteriorating technical indicators, flat financial performance, and valuation pressures despite the company’s strong long-term fundamentals. The downgrade comes amid a challenging market environment and signals caution for investors considering exposure to this mid-cap pharmaceutical stock.

Abbott India Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. This transition is underscored by a combination of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling caution for investors amid a challenging market backdrop.

Abbott India Ltd., a stalwart in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 4 March 2026. This shift reflects nuanced changes across four critical parameters: quality, valuation, financial trend, and technicals. Despite flat quarterly results, the company’s robust fundamentals and evolving technical indicators have prompted a reassessment of its market stance.

Abbott India Ltd. has exhibited a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook across key indicators. The stock’s recent price action, combined with mixed signals from MACD, RSI, and moving averages, suggests cautious optimism for investors amid a volatile pharmaceutical sector backdrop.

Abbott India Ltd., a key player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.26000 today, marking a significant decline in its stock price over the past year. This development comes amid a backdrop of subdued returns and valuation concerns, reflecting the challenges faced by the company in maintaining its market momentum.

Abbott India Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 26 February 2026, providing investors with the latest comprehensive analysis.

Abbott India Ltd. has recently touched a 52-week low, closing just 1.49% above its lowest price point of Rs 26,006.3. This marks a significant moment for the pharmaceutical and biotechnology company as it continues to face headwinds reflected in its stock performance and valuation metrics.

Abbott India Ltd. has touched a new 52-week low of Rs.26006.3 today, marking a significant decline in its stock price amid a year of underwhelming returns and valuation concerns. The stock’s performance contrasts with the broader market’s modest gains, reflecting sector-specific pressures and company-specific metrics that have weighed on investor sentiment.

Abbott India Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Abbott India Ltd. has touched a new 52-week low of Rs.26,306 today, marking a significant decline in its stock price amid a period of sustained underperformance relative to the broader market and its sector peers.